Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

@article{Calvo2004AdministrationOC,
  title={Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.},
  author={Emiliano Calvo and Anthony William Tolcher and Lisa A. Hammond and Amita Patnaik and Johan S de Bono and Irene A. Eiseman and Stephen C. Olson and Peter F. Lenehan and Heather J McCreery and Patricia M. LoRusso and Eric K. Rowinsky},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 21},
  pages={7112-20}
}
PURPOSE To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmacokinetic behavior. EXPERIMENTAL DESIGN Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other week were administered to patients with advanced solid malignancies. Plasma concentration-time data… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

Emerging targeted therapies for breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 44 references

A phase 1 and pharmacokinetic study of CI-1033, a Pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors

M Garrison, A Tolcher, H McCreery
Grunberg SM, editor. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; • 2001
View 4 Excerpts
Highly Influenced

A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors

J Nemunaitis, IA Eiseman, C Cunningham
Grunberg SM, editor. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-June • 2003
View 1 Excerpt

Administration of CI-1033, an irreversible pan-erbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off

EK Rowinsky, M Garrison, PM Lorusso
Clinical Oncology; • 2003
View 2 Excerpts

Similar Papers

Loading similar papers…